Researchers at the University of Kentucky (UK) are part of a groundbreaking clinical trial exploring the use of medical ...

Alzheimer’s Society has warned urgent action is needed to address the projected 51 per cent rise in dementia cases across ...

“Even in individuals who had not yet developed kidney disease, we could see that kidney function was linked to brain atrophy.

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, ...

The headset, developed by researchers at Cornell University in New York, could help reveal how the brain navigates and ...

Overview: In Uganda alone, frequent FMD outbreaks have resulted in losses amounting to millions annually. Between 2015 and ...

As new session begins, Lt. Gov. Patrick calling for lawmakers to pass the Dementia Prevention Research Institute and offer ...

The Lantern at Morning Pointe Alzheimer’s Center of Excellence, Collegedale, has officially completed its remodel.

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

The agency expects to issue a decision by Aug. 31, and it is slated to decide on maintenance dosing for an intravenous form of the drug later this month.

Cases of dementia in the U.S. are expected to steadily rise in the coming years, hitting 1 million annual cases by 2060.